Loading…
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-32M | $-34M | $-33M | -76.5% | - | - |
| 2024 | $0M | $-54M | $-56M | $-43M | -78.7% | - | - |
| 2023 | $0M | $-35M | $-38M | $-30M | -31.3% | - | - |
| 2022 | $0M | $-60M | $-62M | $-57M | -41.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 62.68 | 42.79 | 60.12 | 35.27 |
| Operating Income | -62.68 | -42.79 | -60.12 | -35.27 |
| EBITDA | -60.07 | -35.21 | -53.68 | -31.69 |
| EBIT | -60.33 | -35.47 | -53.93 | -31.94 |
| Pretax Income | -62.02 | -37.54 | -55.85 | -33.85 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income Common Stockholders | -62.02 | -37.54 | -55.85 | -33.85 |
| Total Expenses | 62.68 | 42.79 | 60.12 | 35.27 |
| Interest Expense | 1.69 | 2.07 | 1.93 | 1.91 |
| Interest Income | 2.35 | 7.32 | 6.19 | 3.32 |
| Research And Development | 47.31 | 29.46 | 48.22 | 25.66 |
| Selling General And Administration | 15.37 | 13.34 | 11.89 | 9.60 |
| Normalized EBITDA | -60.07 | -35.21 | -53.68 | -31.69 |
| Normalized Income | -62.02 | -37.54 | -55.85 | -33.85 |
| Basic EPS | -1.06 | -0.64 | -0.94 | -0.56 |
| Diluted EPS | -1.06 | -0.64 | -0.94 | -0.56 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -62.02 | -37.54 | -55.85 | -33.85 |
| Reconciled Depreciation | 0.26 | 0.26 | 0.25 | 0.25 |
| Net Interest Income | 0.66 | 5.25 | 4.27 | 1.42 |
| Net Income From Continuing And Discontinued Operation | -62.02 | -37.54 | -55.85 | -33.85 |
| Total Operating Income As Reported | -62.68 | -42.79 | -60.12 | -35.27 |
| Diluted Average Shares | 58.41 | 58.94 | 59.48 | 60.06 |
| Basic Average Shares | 58.41 | 58.94 | 59.48 | 60.06 |
| Diluted NI Availto Com Stockholders | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income Including Noncontrolling Interests | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income Continuous Operations | -62.02 | -37.54 | -55.85 | -33.85 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.66 | 5.25 | 4.27 | 1.42 |
| Interest Expense Non Operating | 1.69 | 2.07 | 1.93 | 1.91 |
| Interest Income Non Operating | 2.35 | 7.32 | 6.19 | 3.32 |
| General And Administrative Expense | 15.37 | 13.34 | 11.89 | 9.60 |
| Other Gand A | 15.37 | 13.34 | 11.89 | 9.60 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc.this co. | ALDX | $90M | - | 2.04 | -76.5% | -1.02 |
| Cardiff Oncology, Inc. | CRDF | $111M | - | 2.44 | -101.0% | -1.10 |
| Definitive Healthcare Corp. | DH | $99M | - | 0.35 | -36.7% | 5.27 |
| Health Catalyst, Inc. | HCAT | $93M | - | 0.37 | -72.4% | -32.70 |
| MaxCyte, Inc. | MXCT | $87M |
| - |
| 0.51 |
| -26.0% |
| -0.06 |
| biote Corp. | BTMD | $83M | 3.00 | -1.16 | -53.7% | 4.32 |
| Gossamer Bio, Inc. | GOSS | $82M | - | -0.67 | 138.8% | -0.91 |
| Outset Medical, Inc. | OM | $77M | - | 0.60 | -64.3% | -0.14 |
| aTyr Pharma, Inc. | ATYR | $75M | - | 1.11 | -110.2% | -0.11 |
| Peer Median | - | 3.00 | 0.44 | -59.0% | -0.12 | |